Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Glycan Industries develops advanced nutritional ingredients/products for both humans and animals—including beverages enriched with their proprietary “Silicon G57” ingredient—and has a strong emphasis on research into plasma science and quantum medicine. The company also operates non-profit research institutes in Pasadena focused on these areas. They claim FDA GMP compliance for their supplement manufacturing but do not appear to operate as a pharmaceutical CDMO or have traditional drug manufacturing capabilities. No IPO or acquisition events are recorded. The founder/director is Christian Daniel Assoun, who appears to be the principal behind both the UK corporation and US operations. The group’s activities span from commercial nutraceuticals to speculative projects involving space medicine.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Glycan Industries.